Published in Clinical Oncology Week, May 8th, 2006
According to recent research from Germany, "Adjuvant systemic chemotherapy increases survival of primary malignant glioma patients beyond 12-18 months. The only interstitial chemotherapy treatment approved for malignant glioma is Gliadel wafer containing carmustine (BCNU) placed in the resection cavity at surgery."
"Analysis of a large trial by Westphal and colleagues (n=240) showed a 29% risk reduction (p=.03) in the BCNU wafer-treated group over the course of the 30-month trial," explained M....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.